Bensler, LLC Vertex Pharmaceuticals Inc Transaction History

Bensler, LLC

$793 Billion
Q3 2024

A detailed history of Bensler, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Bensler, LLC holds 9,293 shares of VRTX stock, worth $4.67 Million. This represents 0.55% of its overall portfolio holdings.

Number of Shares

9,293

Previous 9,341 0.51%

Holding current value

$4.67 Million

Previous $4.38 Billion 1.29%

% of portfolio

0.55%

Previous 0.59%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 31, 2024	SELL	$460.0 - $505.78 $22,080 - $24,277	-48 Reduced 0.51%	9,293 $4.32 Billion
Q2 2024 Jul 26, 2024	BUY	$392.81 - $485.53 $22,390 - $27,675	57 Added 0.61%	9,341 $4.38 Billion
Q1 2024 Apr 30, 2024	BUY	$407.69 - $446.08 $83,984 - $91,892	206 Added 2.27%	9,284 $3.88 Billion
Q4 2023 Jan 22, 2024	SELL	$343.0 - $410.68 $38,759 - $46,406	-113 Reduced 1.23%	9,078 $3.69 Billion
Q3 2023 Oct 25, 2023	BUY	$338.18 - $362.46 $16,909 - $18,123	50 Added 0.55%	9,191 $3.2 Billion
Q2 2023 Jul 20, 2023	SELL	$314.42 - $351.91 $3,144 - $3,519	-10 Reduced 0.11%	9,141 $3.22 Billion
Q1 2023 Apr 27, 2023	BUY	$283.23 - $323.1 $54,380 - $62,035	192 Added 2.14%	9,151 $2.88 Billion
Q4 2022 Feb 16, 2023	BUY	$285.76 - $321.48 $3,143 - $3,536	11 Added 0.12%	8,959 $2.59 Billion
Q3 2022 Feb 16, 2023	BUY	$273.83 - $305.53 $63,254 - $70,577	231 Added 2.65%	8,948 $2.59 Billion
Q2 2022 Feb 16, 2023	BUY	$234.96 - $292.55 $9,868 - $12,287	42 Added 0.48%	8,717 $2.46 Billion
Q1 2022 Feb 16, 2023	BUY	$221.42 - $260.97 $2,214 - $2,609	10 Added 0.12%	8,675 $2.26 Billion
Q4 2021 Feb 16, 2023	BUY	$177.01 - $223.45 $1.53 Million - $1.94 Million	8,665 New	8,665 $1.9 Billion

Others Institutions Holding VRTX

# of Institutions

1,716

Shares Held

225M

Call Options Held

1.19M

Put Options Held

1.56M

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $129B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Bensler, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bensler, LLC with notifications on news.

Account